INNODIA BOARD
INNODIA has a board that provides strategic decision-making, guidance oversight and accountability. The board is made of one representative from each founding members, prime members, and funders; one representative from full members elected by the general assembly; and one associate from the community of people and families living with type 1 diabetes (INPACT) for a maximum of 15 board of directors.
INNODIA BOARD
INNODIA has a board that provides strategic decision-making, guidance oversight and accountability. The board is made of one representative from each founding members, prime members, and funders; one representative from full members elected by the general assembly; and one associate from the community of people and families living with type 1 diabetes (INPACT) for a maximum of 15 board of directors.
INNODIA MANAGEMENT TEAM
INNODIA is managed by a team of professionals who steer the organization, implement the organization’s strategy and translate into actions all major decisions taken by the governing board and the general assembly. Meet the team!
INNODIA MANAGEMENT TEAM
INNODIA is managed by a team of professionals who steer the organization, implement the organization’s strategy and translate into actions all major decisions taken by the governing board and the general assembly. Meet the team!
Open positions in the management team
Open applications
Don’t see a vacancy that matches your profile? We’re always happy to hear from motivated people who want to contribute to our mission. Send your CV and a short motivation letter to info@innodia.org.
INNODIA GENERAL ASSEMBLY
The INNODIA general assembly is made of representatives from all members and it has the power to admit new members and approve the organisational strategies and policies. In addition to all board members, one representative from every full member has the voting rights in the general assembly (list of INNODIA full members below).
INNODIA PEOPLE and FAMILIES LIVING WITH TYPE 1 DIABETES (INPACT)
INNODIA originates from and is pointed towards people and families living with type 1 diabetes. We are based on a community of experts capable of influencing the drug-development process from research to clinical development.
